ZURA BIO LIMITED Accrued Professional Fees, Current
ZURA BIO LIMITED (ZURA) had Accrued Professional Fees, Current of $1.40 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Accrued Liabilities, Current
us-gaap:AccruedProfessionalFeesCurrent · last filed 2026-08-11
- 2026-06-30: Accrued Professional Fees, Current $1.40M.
- 2026-03-31: Accrued Professional Fees, Current $1.41M.
- 2025-12-31: Accrued Professional Fees, Current $559.00K.
- 2025-09-30: Accrued Professional Fees, Current $869.00K.
| Period end | Accrued Professional Fees, Current |
|---|---|
| 2026-06-30 | $1.40M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $1.41M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $559.00K 10-Q · filed 2026-08-11 |
| 2025-09-30 | $869.00K 10-Q · filed 2025-11-13 |
| 2025-06-30 | $428.00K 10-Q · filed 2025-08-14 |
| 2025-03-31 | $796.00K 10-Q · filed 2025-05-08 |
| 2024-12-31 | $318.00K 10-K · filed 2026-03-19 |
| 2024-09-30 | $948.00K 10-Q · filed 2024-11-07 |
| 2023-12-31 | $150.00K 10-K · filed 2025-03-25 |
| 2023-09-30 | $133.00K 10-Q · filed 2023-11-13 |
| 2023-06-30 | $1.21M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $107.00K 10-Q · filed 2023-05-12 |
| 2022-12-31 | $308.00K 10-Q · filed 2023-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |